摘要
潜在的瘢痕疙瘩发病的分子机制尚不清楚。microRNA(miRNA)是一类小型的调控RNA,已涌现出一批如转录后基因抑制因子,参与皮肤病的多种病理生理学过程。我们研究了患者血清中miRNA的表达谱去破译参与瘢痕疙瘩疾病发展的复杂因素。使用包含了人类的成熟和前体miRNA序列的miRNA芯片去表征miRNA表达谱在9例瘢痕疙瘩患者和7例正常对照组的血清中。实时定量PCR验证miRNA的表达。差异表达的miRNA的假定目标通过生物信息学进行了功能注释。miRNA芯片鉴定了37个差异表达的miRNA(17上调和20下调)在瘢痕疙瘩患者中,同健康对照相比。功能注释表明,这些差异表达的miRNA的目标在信号通路上富集,是疤痕形成和伤口愈合的必不可少的原因。miRNA的表达谱在瘢痕疙瘩患者中被改变,这为其的起始和进展的分子机制提供线索。miRNA可能部分通过影响相关的瘢痕疙瘩发病机制中的关键信号通路而导致瘢痕疙瘩。
关键词: 瘢痕疙瘩;微小核糖核酸;血清;发病病因;疤痕;病因。
Current Molecular Medicine
Title:Serum miRNAs Signature Plays an Important Role in Keloid Disease
Volume: 16 Issue: 5
Author(s): Y. Luan, Y. Liu, C. Liu, Q. Lin, F. He, X. Dong, Z. Xiao
Affiliation:
关键词: 瘢痕疙瘩;微小核糖核酸;血清;发病病因;疤痕;病因。
摘要: The molecular mechanism underlying the pathogenesis of keloid is largely unknown. MicroRNA (miRNA) is a class of small regulatory RNA that has emerged as a group of posttranscriptional gene repressors, participating in diverse pathophysiological processes of skin diseases. We investigated the expression profiles of miRNAs in the sera of patients to decipher the complicated factors involved in the development of keloid disease. MiRNA expression profiling in the sera from 9 keloid patients and 7 normal controls were characterized using a miRNA microarray containing established human mature and precursor miRNA sequences. Quantitative real-time PCR was performed to confirm the expression of miRNAs. The putative targets of differentially expressed miRNAs were functionally annotated by bioinformatics. MiRNA microarray analysis identified 37 differentially expressed miRNAs (17 upregulated and 20 downregulated) in keloid patients, compared to the healthy controls. Functional annotations revealed that the targets of those differentially expressed miRNAs were enriched in signaling pathways essential for scar formation and wound healing. The expression profiling of miRNAs is altered in the keloid, providing a clue for the molecular mechanisms underlying its initiation and progression. MiRNAs may partly contribute to the etiology of keloids by affecting the critical signaling pathways relevant to keloid pathogenesis.
Export Options
About this article
Cite this article as:
Y. Luan, Y. Liu, C. Liu, Q. Lin, F. He, X. Dong, Z. Xiao , Serum miRNAs Signature Plays an Important Role in Keloid Disease, Current Molecular Medicine 2016; 16 (5) . https://dx.doi.org/10.2174/1566524016666160429121345
DOI https://dx.doi.org/10.2174/1566524016666160429121345 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Recent Patents on Heat Shock Proteins Targeting Antibodies
Recent Patents on Anti-Cancer Drug Discovery Chip-Based High Throughput Screening of Herbal Medicines
Combinatorial Chemistry & High Throughput Screening A panoramic view of chronic liver diseases and natural remedies reported in Traditional Persian Medicine
Current Pharmaceutical Design Human Galectin-1 in Multiple Cancers: A Privileged Molecular Target in Oncology
Mini-Reviews in Medicinal Chemistry Targeting Dopaminergic System for Treating Nicotine Dependence
Central Nervous System Agents in Medicinal Chemistry Biodegradable Composite Scaffolds: A Strategy to Modulate Stem Cell Behaviour
Recent Patents on Drug Delivery & Formulation Biomedical Applications of Gold Nanoparticles
Current Topics in Medicinal Chemistry Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Lesson Learned from Nature for the Development of Novel Anti-Cancer Agents: Implication of Isoflavone, Curcumin, and their Synthetic Analogs
Current Pharmaceutical Design Pioglitazone, Bladder Cancer, and the Presumption of Innocence
Current Drug Safety Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Zebrafish Model in Drug Safety Assessment
Current Pharmaceutical Design The Use of SIFT-MS in Profiling the Faecal Volatile Metabolome in Horses with Colic: A Pilot Study
Current Analytical Chemistry Cancer and Treatment Modalities
Current Cancer Therapy Reviews Review of 5-HT4R Ligands: State of Art and Clinical Applications
Current Topics in Medicinal Chemistry Update on the Rheumatologic Manifestations of Malignancy
Current Cancer Therapy Reviews Antimicrobial Peptides and Peptaibols, Substitutes for Conventional Antibiotics
Current Pharmaceutical Design Photodynamic Therapy using Carbohydrate Conjugated Porphyrins
Drug Design Reviews - Online (Discontinued)